Soft Tissue Sarcoma Results. June 2018
|
|
- Cordelia Reynolds
- 5 years ago
- Views:
Transcription
1 Soft Tissue Sarcoma Results June 2018
2 IMPORTANT NOTICE AND DISCLAIMER IMPORTANT: You must read the following before continuing. In accessing this document, you agree to be bound by the following terms and conditions. This document has been prepared by Nanobiotix SA (together with its subsidiaries, the Group ) and is for information purposes only. The content of this document is provisional and for information purposes only and is not to be construed as providing investment advice. The information, statements and opinions contained in this document (the Information ) are provided as of the date of this document only and may be subject to significant changes at any time without notice. Neither the Group, nor its advisors, nor any other person is under any obligation to update the Information. Subject to applicable law, none of the Company or its advisors accepts any responsibility whatsoever and makes no representation or warranty, express or implied, as to the fairness, accuracy, completeness or correctness of the Information. The Information has not been subject to independent verification and is qualified in its entirety by the business, financial and other information that the Group is require d to publish in accordance with the rules, regulations and practices applicable to companies listed on Euronext Paris, including in particular the risk factors in the Company s Registration Document (Document de Référence) filed with the French Financial Markets Authority (Autorité des marchés financiers) under number D on April 28, 2017, in any other periodic report and in any other press release, which are available free of charge on the websites of the Group ( and/or the AMF ( This document contains information on the use of the Group's products and its competitive position. Some of the Information is from third parties. While this third party information has been obtained from sources believed to be reliable, there is no guarantee of the accuracy or completeness of such data. In addition, certain of the industry and market data comes from the Group's own internal research and estimates based on the knowledge and experience of the Group's management. While the Group believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the industry, market or competitive position data contained in the Information. The Information is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of, or located in, any locality, state, country or other jurisdiction where such distribution or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. The Information does not constitute or form part of, and should not be construed as an offer or the solicitation of an offer to subscribe for or purchase of any securities. No public offering of securities may be conducted in France prior to the delivery by the French Financial Markets Authority of a visa on a prospectus that complies with the provisions of Directive 2003/71/CE as amended. This document is for information purposes only and does not constitute an offering document or an offer of securities to the public in the Unite d Kingdom to which section 85 of the Financial Services and Markets Act 2000 of the United Kingdom applies. Securities may not be offered or sold in the United States absent registration under the US Securities Act of 1933, as amended, or an exemption from registration thereunder. This document contains certain forward-looking statements. All statements in this document other than statements of historical fact are or may be deemed to be forward looking statements. These statements are not guarantees of the Group's future performance. These forward-looking statements relate without limitation to the Group's future prospects, developments, marketing strategy regulatory calendar, clinical milestones, assumptions and hypothesis, clinical development approach and financial requirements and are based on analyses of earnings forecasts and estimates of amounts not yet determinable and other financial and non-financial information. Forward-looking statements are subject to a variety of risks and uncertainties as they relate to future events and are dependent on circumstances that may or may not materialize in the future. Forward-looking statements cannot, under any circumstance, be construed as a guarantee of the Group's future performance as to strategic, regulatory, fi nancial or other matters, and the Group s actual performance, including its financial position, results and cash flow, as well as the trends in the sector in which the Group operates, may differ materially from those proposed or reflected in the forward-looking statements contained in this document. Even if the Group s performance, including its financial position, results, cash-flows and developments in the sector in which the Group operates were to conform to the forward-looking statements contained in this document, such results or developments cannot be construed as a reliable indication of the Group's future results or developments. The Group expressly declines any obligation to update or to confirm projections or estimates made by analysts or to make public any correction to any prospective information in order to reflect an event or circumstance that may occur after the date of this document. 2
3 NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3 The trial achieved its primary endpoint of pathological Complete Response Rate (pcrr) The trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrates significant superiority and clinical benefits for patients versus standard of care Safety profile confirmed This randomized trial validates the first in class mode of action of NBTXR3 3
4 One of the largest oncology markets with large unmet medical need Cancer patients 60% RTx More than 60% of all cancer patients receive Radiation Therapy Unmet medical need improve local control of tumor reduce relapse rate improve metastatic patient outcome More than 9 million / year Source: * World Health Organization (2014); **RADIATION THERAPY EQUIPMENT A global strategic business report 08/06 4
5 Nanobiotix targets radiation therapy - one of the largest oncology markets with minimal competition Conventional radiation therapy Around 60%* of cancer patients receive radiotherapy as a local treatment TUMOR Destroys any cancer cell at the right dose 50 cm Important limitations due to toxicity on healthy tissues 20 cm 100 photons at 6 MEV MeV Energy deposition 20 cm Xray track How to improve the energy dose within the tumor without damaging healthy tissues? Source: * RADIATION THERAPY EQUIPMENT A global strategic business report 08/2006 5
6 Solution: NBTXR3 maximizes Xray absorption in the tumor Technology key features: 1 Nanosized to enter cell 50nm 2 Designed to strongly absorb Xrays 3 Designed to be non-toxic HfO2 nanoparticles; electron microscopy picture 50 nanometer HfO 2 * particles were chosen because they have the best ratio for X-ray absorption and non-toxicity IP: concept and products protected by 10 patent families until at least 2029 * HfO2: Hafnium Oxide Source: Maggiorella et al. (2012) 6
7 NBTXR3 has a physical mode of action: Increase dose absorption & deposition in the tumor Radiotherapy Radiotherapy with NBTXR3 9X Dose* around nanoparticles *Note: Dose enhancement determined by montecarlo simulation (CEA Saclay, France) 7
8 NBTXR3 universal MOA triggering cellular destruction and adaptative immune response NBTXR3 +RTx large energy deposition in a nano-volume physical damage Clustered Nanoparticles in cytoplasm Dendritic cell activation Structural Damage DNA damage Stress Immunogenic Cell Death Sting pathway activation CD4 & CD8 activation Tumor Infiltration and Cell Killing Direct Cell Death (Apoptosis, Necrosis, ) 8
9 NBTXR3 First in Class Radioenhancer Physical Mode of Action that could work across all solid tumors Only one administration Fits into existing standard of care No change in equipment No change in current patient flow No change in protocol One product fitting in current practice helping millions of patients every year 9
10 NBTXR3 already used in clinical trials across EU, US and Asia 74 clinical centers using NBTXR3 Advanced development / pre-commercialization STS, H&N, Prostate, Rectum, NSCLC, HCC, Liver Mets 7 clinical trials 10 patient populations More than 200 patients recruited in clinical trials 400 MDs involved in clinical trials More than 70 clinical centers (US, EU, Asia) CE mark filed for first Proof-of- Concept application (STS) 10
11 PII/III in Soft Tissue Sarcomas (STS) Topline Data 11
12 Soft Tissue Sarcoma: epidemiology Sarcomas: a complex family of rare cancers Cancers of the connective tissues are categorized in two major groups: soft tissue sarcoma (STS) and bone sarcoma 60% start in the arms and legs, 30% in the abdomen or torso and 10% in the head or neck. STS develops from the muscles, fibrous tissues, fat, blood vessels, nerves, etc. 50 different subtypes of STS Incidence of sarcomas in 2016: All Study population North America 25,000 9,000 Europe 55,000 20,000 NORTH AMERICA 25,000 cases EUROPE (ALL) 55,000 cases Ref: Datamonitor ref. DMKC
13 Soft tissue sarcoma: patient population Soft tissue sarcoma of the extremities* and trunk wall Locally advanced soft tissue sarcoma, newly diagnosed or relapsed tumor: High risk tumor Borderline unresectable tumor or unfeasible carcinological surgical resection Neoadjuvant radiotherapy is used as a Standard of Care in this population Main advantages (long term): Lower late morbidity (fibrosis, bone fracture, etc.) Improved long-term functional outcome Improved quality of life Unmet medical need for locally advanced soft tissue sarcoma * Arms and legs 13
14 Soft Tissue Sarcoma: treatment objectives Ideal patient outcome in preoperative setting Removal of tumor No remaining tumor cells in the body after surgery Surgically remove (resect) tumor to improve patients survival and quality of life Surgery 14
15 Randomization Design of Phase II/III study in soft tissue sarcoma Study design STS phase II/III Population: Patients with locally advanced soft tissue sarcoma of the extremity and trunk wall 180 patients recruited 162 patients evaluable Multi center, open-label, randomized trial with active control Test arm NBTXR3 with RTx 50Gy 43 sites 13 countries EU and Asia > 10 STS subtypes 1:1 RTx 50Gy Comparator arm Stratification population: myxoid Lps vs others 15
16 Phase II/III Study in Soft Tissue Sarcoma Flowchart and study design RTx + NBTXR3 (87 patients) RTx (89 patients) Day 1 One time Intratumoral injection End of treatment Surgery Session of RTx according to standard of care (25 x 2 Gy) Surgery Population: Patients with locally advanced soft tissue sarcoma of the extremity and trunk wall Locally advanced soft tissue sarcoma, newly diagnosed or relapsed tumor High risk tumor Unresectable tumor or unfeasible carcinological surgical resection 16
17 Phase II/III study in STS: Endpoints Primary endpoint: Pathological complete response rate (pcrr) as per EORTC Guidelines Secondary endpoints: Safety Operability (surgery margin, R0, ) Pathological Response (pr) Amputation rate Topline data Other exploratory endpoints will be available later 17
18 Two important clinical end points in STS Pathological response & Surgery Margin Primary Endpoint Pathological response 5% viable cells > 5% viable cells Pathological response: % of dead tumor cells Pathological complete response: 95% dead tumor cells ( 5% viable tumor cells) 18
19 Two important clinical end points in STS Pathological response & Surgery Margin Primary Endpoint Pathological response 5% viable cells > 5% viable cells Pathological response: % of dead tumor cells Pathological complete response: 95% dead tumor cells ( 5% viable tumor cells) Secondary Endpoint Surgery (Resection) margin R0 Negative margin 19
20 Pathological response: a direct measure of efficacy Pathological response: % of dead tumor cells Pathological complete response: 95% dead tumor cells ( 5% viable tumor cells) pr: pathological Response Measures the efficacy of cell killing pcrr: pathological Complete Response Rate Measures the optimum efficacy of cell killing Is a potential surrogate for systemic efficacy 20
21 Pathological response as a surrogate for survival Schaefer et al., 2017 pcrr (defined as < 5% viable cancer cells) shows a global trend in relation with OS Unlike in Breast Cancer, pcrr is not significantly correlated with survival in STS given the current state of data 21
22 Surgery / Resection margin: a key endpoint for clinical benefit R0 Negative margin R1 Positive margins R2 Amputation 22
23 R0 / Resection margin increases PFS & OS for patients R0 R1 R2 Resection limits Negative margin Positive margin Amputation Local recurrence-free survival (Local relapse) Negative margin Positive margin Negative margins: R0 surgery significantly correlated to patient benefits like Progression Free Survival (local and distant) and Overall Survival 23
24 Quality of initial surgery (% of patients) Quality of initial surgery (% of patients) R0 Resection margins in Study site in line with French STS Center of Excellence R0 Resection Margin in: Specialized centers 56% Non specialized centers 13% STS Study Control Arm 70 Resection Margin by center 70 Resection Margin in 301 Study R0 R1 R2 Outside NETSARC Non-specialized Center Adapted from Blay et al., 2018 (add full reference Limbs sarcomas operated (n > 240, France) Within NETSARC Specialized Center R0 R1 R2 RT (Control Arm) N=89 24
25 NBTXR3 impact on the standard of care (planned radiation and surgery) No change in Median Relative Radiation therapy dose intensity No change in Median Duration of radiotherapy schedule (days) No change in % of surgery performed The study confirmed: Feasibility of injection No change in dosage and schedule of current radiotherapy standard of care Good local tolerance (similar radiation safety in both arms) Manageable acute immunological reaction occurring at the time of injection No impact on planned radiation and surgery *Relative radiation therapy Dose Intensity = (Actual Dose Intensity / Planned Dose Intensity) ITT FAS (Full Analysis Set) 25
26 % of patients with pcr pcrr: the study met its primary end point Pathological Complete Response 16.1 p-value * 7.9 Complete Pathological Response NBTXR3 activated by radiotherapy (N=87) Radiotherapy alone (N=89) More than twice as many patients having a Pathological Complete Response ( 5% viable cells) Statistically significant at an adjusted α of 0,04575 ITT FAS (Full Analysis Set) 26
27 Pathological Response > 90% correlates with superior OS Salah et al. (2018) Meta-analysis on 1663 STS patients Tumor necrosis > 90% following preoperative treatment (i.e. < 10% viable cancer cells) was associated with decreased recurrence risk and superior OS. 27
28 % of patients with R0 resection margins R0 rate: the study also met its secondary endpoint Resection Margin p-value * R0 64 NBTXR3 activated by radiotherapy (N=87) Radiotherapy alone (N=89) Significant 20% relative increase in R0 rate in the NBTXR3 arm Statistically significant at an α of 5% ITT FAS (Full Analysis Set) 28
29 PI quotes Pr. Sylvie Bonvalot, MD, Head of the Sarcoma and Complex Tumor Surgery Unit at Institut Curie, Paris, France and Principal Investigator of the PII/III study commented Data are exceptional and show without any doubt an improvement of radiation therapy impact with a significant number of complete response. NBTXR3 can bring real benefit to patients and it can change the standard of care. This innovation will play a role in many other indications and particularly where radiation is used alone. Pr Jean-Yves Blay, MD, Director of the Centre Léon Bérard, Lyon, France, commented I am amazed by the difference of Response Rate, it is extremely uncommon to double the Rate of Complete histological Response and I do not see any other strategy able to accomplish that. Even more impressive is the R0 rate, which is increased by more than 20% compared to an average rate of 64%. This difference is really impressive, considering that R0 impacts patients relapses and survival. David Raben MD, Professor of Radiation Oncology, University of Colorado Cancer Center, CO, USA, commented: These results from a Phase III study are impressive in a notoriously difficult disease like Soft Tissue Sarcoma. These cancers are generally less sensitive to radiation and previous attempts to improve local control with chemo-radiation regimens were considered too toxic. This study substantiates the medical benefit of safely enhancing the effect of radiation therapy with novel physics-based approaches delivered locally within the cancer. In addition, this product may potentiate a pro-inflammatory environment suitable for immune enabling or DNA damage inhibitor drugs. These findings set the foundation for additional studies in areas such as head and neck cancer and perhaps in areas such as high-risk prostate, bladder or pancreas cancer. 29
30 NBTXR3 Phase II/III 301 study in Soft Tissue Sarcoma Conclusion The trial achieved its primary endpoint pathological Complete Response Rate (pcrr) The trial achieved its secondary endpoint in operability (R0 rate) NBTXR3 demonstrates significant superiority and clinical benefits for patients versus standard of care Safety profile confirmed This randomized trial validated the first in class Mode of Action of NBTXR3 30
PLEO-CMT Top-line Results. Presentation October 16, 2018
PLEO-CMT Top-line Results Presentation October 16, 2018 Disclaimer References herein to this presentation (the Presentation ) shall mean and include this document, any oral presentation accompanying this
More informationQ4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB
More informationThe Lipid Metabolism Company. Corporate Presentation March 2018
The Lipid Metabolism Company Corporate Presentation March 2018 Disclaimer This document has been prepared by Cerenis Therapeutics (the "Company") and is for information purposes only. The information and
More informationNOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX
Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,
More informationWorld leader in navigated, non-invasive brain stimulation therapy and diagnosis
World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,
More informationTamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
More informationPXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes
PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux
More informationBrisa Concessão Rodoviária. 1Q 2017 Traffic Update
Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according
More informationInvestor presentation. Bioshares Biotech Summit July 2017
Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available
More informationPhase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell
Phase III ARISER trial data ASCO 2013 RENCAREX - Unique targeted antibody therapy for adjuvant treatment of non-metastatic clear cell renal cell carcinoma patients June 2013 Carbonic Anhydrase IX (CAIX):
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationFor personal use only
Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by
More informationXXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology
Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,
More informationZogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
Zogenix Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationCalliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO
Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationAnnual Results 2017 & Business Update 13 April 2018
Annual Results 2017 & Business Update 13 April 2018 1 Disclaimer These slides and the accompanying oral presentation contain forward-looking statements and information. Forward-looking statements are subject
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationBuilding a Global Leader in Orphan Oncology. June 2017
Building a Global Leader in Orphan Oncology Important Information IMPORTANT: You must read the following before continuing. In accessing this document, you agree to be bound by the following terms and
More informationResults of the TITAN study for Caplacizumab
Results of the TITAN study for Webcast presentation 17th June 2014 Nanobodies - Inspired by nature Forward looking statements Certain statements, beliefs and opinions in this presentation are forward-looking,
More informationCompany presentation. Claudio Bordignon, Chairman and CEO. Jefferies Global Healthcare Conference New York, 7 June 2012
Company presentation Claudio Bordignon, Chairman and CEO Jefferies Global Healthcare Conference New York, 7 June 2012 Forward-looking statements The presentation contains certain forward-looking statements.
More information37th Annual J.P. Morgan Healthcare Conference TWO (Taipei Exchange) January 9, 2019
37th Annual J.P. Morgan Healthcare Conference 4162.TWO (Taipei Exchange) January 9, 2019 1 Mission & Vision Mission Unlock value for promising therapeutic candidates & Extend patients lives Vision Top
More informationOxurion NV Business Update Q End Q cash position 95.1 million
Oxurion NV Business Update Q3 2018 Shareholders Approval and Launch of Oxurion NV as new Company Name First patient enrolled in Phase 1 study evaluating THR-687, a Novel Pan-RGD Integrin Antagonist, for
More informationSTUDY 1 PHASE 3 TOP-LINE RESULTS. September 2017
STUDY 1 PHASE 3 TOP-LINE RESULTS September 2017 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,
More informationAcasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites
More informationACACIA PHARMA ANNOUNCES ITS INTENTION TO LAUNCH AN INITIAL GLOBAL OFFERING AND TO LIST ITS SHARES ON EURONEXT BRUSSELS
This announcement is an advertisement for the purposes of the Prospectus Rules of the Financial Conduct Authority ( FCA ) and not a prospectus and not an offer of securities for sale in any jurisdiction,
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More information8 of 21 (38.1%) Achieved RECIST v1.1 Durable Complete Response (CR) in Predicted Anti-PD-1 Non-Responder Melanoma Patients at 24 Weeks
October 19, 2017 OncoSec Presents Positive Phase 2 Data for ImmunoPulse IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non- Responder
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationLiquid Biopsies. Next Generation Cancer Molecular Diagnostics
Liquid Biopsies Next Generation Cancer Molecular Diagnostics Forward Looking Statements 2 Statements pertaining to future financial and/or operating results, future research, diagnostic tests and technology
More informationCompany overview. Highlights for the 1 st quarter 2018 (January-March)
Company overview Vaccibody is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies. The company is a leader in the rapidly developing field of
More informationBayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies
More informationFIRSTQUARTER2018 RESULTSPRESENTATION
FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection
More informationNOXOPHARM POSTS CORPORATE PRESENTATION AHEAD OF CONFERENCE ASX: NOX. Presentation at Singapore Investor Conference Review of first year of operation
Date 8 August 2017 Sydney, Australia ASX: NOX Noxopharm Limited ABN 50 608 966 123 Registered Office: Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia Operations Office: Suite 3 Level 4 828 Pacific
More informationAdvancing Pancreatic & Liver Cancer Treatment
ASX.OSL Advancing Pancreatic & Liver Cancer Treatment Australian Biotech Invest 2017 October 24 th Melbourne 1 Important notice This Presentation has been prepared by Ltd (ASX:OSL) (OncoSil or the Company)
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationPancreatic cancer study Atu027-I-02 Interim analysis. 1 June 2015
Pancreatic cancer study Atu027-I-02 Interim analysis 1 June 2015 Disclaimer The information contained in this presentation is being supplied and communicated to you on a confidential basis solely for your
More informationIpilimumab ASCO Data Review and Discussion Webcast. Monday, June 2, 2008
Ipilimumab ASCO Data Review and Discussion Webcast Monday, June 2, 2008 Slide 2 Forward Looking Statements Except for historical information, the matters contained in this slide presentation may constitute
More informationGenta Incorporated. A Multiproduct Late-Stage Oncology Company
Genta Incorporated A Multiproduct Late-Stage Oncology Company This presentation may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking
More informationNitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam
Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationBusiness Update & Financial Results for Q1 2018
Business Update & Financial Results for Q1 2018 May 15, 2018 Disclaimer The statements made in this presentation may include forward-looking statements regarding the future operations of ERYTECH Pharma
More informationVAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018
VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationVerona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva )
Press release 7 September 2017 Verona Pharma Announces Positive Top-Line Data from Phase 2a Clinical Trial in COPD with RPL554 Dosed in Addition to Tiotropium (Spiriva ) Achieved significant and clinically
More informationAGM Presentation For the year to 30 September February 2016
AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationArming the patient s immune system to fight cancer
Arming the patient s immune system to fight cancer Redeye - Fight Cancer Seminar 10 th March 2017 Øystein Soug, CEO Important notice and disclaimer This report contains certain forward-looking statements
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationMagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer
MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationIMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics
IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Rodman & Renshaw 19 th Annual Global Investment Conference Michael R. Garone, Principal Executive Officer and CFO Forward-Looking
More informationIpsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine
PRESS RELEASE Ipsen announces CELESTIAL phase 3 pivotal trial results in the New England Journal of Medicine Trial results formed the basis of regulatory filings in the U.S. and European Union for CABOMETYX
More informationMerrimack Pharmaceuticals: A Refocused R&D Company January 2017
Merrimack Pharmaceuticals: A Refocused R&D Company January 2017 Forward Looking Statements This presentation contains forward-looking statements of the Company that involve substantial risks and uncertainties.
More informationAbout X-Linked Hypophosphatemia (XLH)
Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal
More informationEpendymoma Programme Synopsis
Ependymoma Programme Synopsis TITLE SPONSOR PROTOCOL NUMBER EUDRACT NUMBER NATIONAL INVESTIGATOR- COORDINATOR SIOP Ependymoma program II: An International Clinical Program for the diagnosis and treatment
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationFrédéric Triebel MD, PhD World Immunotherapy Congress Basel, October 30, 2018
Two ACTive immunotherapies in melanoma (TACTI-mel): results of a phase I trial combining a soluble LAG-3 receptor (Eftilagimod Alpha) with Pembrolizumab Frédéric Triebel MD, PhD World Immunotherapy Congress
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information3Q 2016 presentation
Arming the patient s immune system to fight cancer 3Q 2016 presentation 17 November 2016 Important notice and disclaimer This report contains certain forward-looking statements based on uncertainty, since
More informationOncoSec Provides 2018 Business Outlook
January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationRegorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer
News Release Not intended for U.S. and UK Media Bayer AG Communications, Government Relations & Corporate Brand 51368 Leverkusen Germany Tel. +49 214 30-0 www.news.bayer.com Regorafenib from Bayer Submitted
More informationGLPG1690 FLORA topline results
GLPG1690 FLORA topline results Webcast presentation 10 August 2017 Disclaimer This presentation contains forward-looking statements, including (without limitation) statements concerning the potential activity
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationDeveloping Xanamem for Alzheimer s Dementia
Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen
More informationFor personal use only. General Meeting 6 March 2014
General Meeting 6 March 2014 Disclaimer Certain statements made in this presentation are forward looking statements within the meaning of the safe harbour provisions of the United States Private Securities
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationDCVax Novel Personalized Immunotherapies for Solid Tumors
DCVax Novel Personalized Immunotherapies for Solid Tumors Phaciliate Immunotherapy World Forum January 26, 2016 Disclaimer Certain statements made in this presentation are forward-looking statements of
More informationDISCLOSEABLE AND CONNECTED TRANSACTION AND PROPOSED APPOINTMENT OF CHIEF EXECUTIVE OFFICER
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More informationMainstay Medical Announces Headline Results from ReActiv8-B Clinical Study
Mainstay Medical Announces Headline Results from ReActiv8-B Clinical Study Responder rates at 120 days for treatment and active control groups were 56% vs. 47%; statistically significant difference on
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationXanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease
XanADu: A Phase II trial of Xanamem TM in mild Alzheimer's disease Dr Bill Ketelbey CEO 17TH ALZHEIMER'S AUSTRALIA BIENNIAL NATIONAL DEMENTIA CONFERENCE 19 OCTOBER 2017 Disclaimer This presentation has
More informationINODIFTAGENE Recombinant DNA Gene Therapy for Bladder Cancer
INODIFTAGENE Recombinant DNA Gene Therapy for Bladder Cancer 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of U.S. federal securities laws and Israeli
More informationMAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE
MAGFORCE AG FIGHTING CANCER WITH NANO MEDICINE 2014, Berlin, Germany 2 EXECUTIVE SUMMARY Company Profile Headquartered in Berlin, Germany Current Management Team: B. Lipps, H. Tawfik, C. von Volkmann Frankfurt
More informationPSMA-617 License Transaction. October 2, 2017
PSMA-617 License Transaction October 2, 2017 Forward Looking Statements Certain of the statements made in this presentation are forward looking, such as those, among others, relating to future spending,
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer March 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward-looking statements. Rexahn's actual results may
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationINODIFTAGENE Gene Therapy for Bladder Cancer
INODIFTAGENE Gene Therapy for Bladder Cancer 1 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of U.S. federal securities laws and Israeli securities laws
More informationCOMPANY PRESENTATION. January 2019
COMPANY PRESENTATION January 2019 1 FORWARD-LOOKING STATEMENT This presentation does not constitute or form part of any offer or invitation to purchase or subscribe for, or any offer to underwrite or otherwise
More informationVolitionRx Announces First Quarter 2016 Financial Results and Business Update
May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused
More informationThe solid choice for Omega-3
The solid choice for Omega-3 The highest-load powder in its class. Superior bioavailability, stability and compressibility. Enabling smaller, simpler and more satisfying supplements. Unmatched properties
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Imfinzi) Reference Number: CP.PHAR.339 Effective Date: 07.01.17 Last Review Date: 05.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationMolecular Diagnostic Solutions for Urologic Cancer
1 Molecular Diagnostic Solutions for Urologic Cancer 2017 First Half Results Presented on 31 August 2017 Dr. Jan Groen, President & CEO Mr. Jean-Marc Roelandt, EVP & CFO 2 Forward looking statement This
More information